Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | CD19R(EQ)28zetaEGFRt+ Tn/mem cells |
| Trade Name | |
| Synonyms | CD19R(EQ)28zeta/EGFRt-expressing naive and memory T cells |
| Drug Descriptions |
CD19R(EQ)28zetaEGFRt+ Tn/mem cells consist of a preparation of CD62L-positive naive and memory T-lymphocytes engineered to express a modified CD19-targeting (CD19R(EQ)) chimeric antigen receptor (CAR) as well as CD28 and CD3-zeta signaling domains, as well as a truncated EGFR (EGFRt), which potentially induces toxicity against tumor cells expressing CD19 (NCI Drug Dictionary). |
| DrugClasses | CD19 Immune Cell Therapy 72 |
| CAS Registry Number | NA |
| NCIT ID | C133073 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Acalabrutinib + CD19R(EQ)28zetaEGFRt+ Tn/mem cells | Acalabrutinib CD19R(EQ)28zetaEGFRt+ Tn/mem cells | 0 | 1 |
| CD19R(EQ)28zetaEGFRt+ Tn/mem cells | CD19R(EQ)28zetaEGFRt+ Tn/mem cells | 0 | 0 |